司太立(603520.SH)及全資子公司與恆瑞醫藥簽署藥品合作協議 推進在碘造影劑製劑領域的發展
格隆匯5月12日丨司太立(603520.SH)公佈,公司全資子公司上海司太立製藥有限公司(“上海司太立”)向中國國家藥品監督管理局(“NMPA”)提交了碘海醇注射液及碘帕醇注射液(“合作產品”)的註冊申請,目前處於受理待批階段。為進一步推進公司在碘造影劑製劑領域的發展,公司及上海司太立與江蘇恆瑞醫藥股份有限公司(“恆瑞醫藥”)有意將對方作為其在碘造影劑領域的合作伙伴,合作開拓市場,雙方於2020年5月11日簽署了《合作協議》。
該協議符合公司的戰略發展需要,協議雙方將針對該協議約定範圍開展合作產品的研發、註冊及商業化推廣,有利於加深公司與恆瑞醫藥在碘造影劑領域的合作與發展。
該協議雖約定合作產品的定價機制及利潤分配,但後續合作產品獲批後,恆瑞醫藥將根據商業化推廣的情況向公司提供具體的採購訂單以及公司根據合作產品的製造成本,最終確定合作產品的具體的採購價格及數量,並根據商業化推廣的實際銷售情況來確定具體的收益情況,因此該協議對公司業績的影響存在不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.